Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Non-Current Liabilities of $106.0 billion for Q2 2026, down 3.21% sequentially from $109.5 billion in Q1 2026, and down 6.83% YoY from $113.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Total Non-Current Liabilities for 18 years, with the latest figure at $106.0 billion in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 6.83% year-over-year to $106.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.0 billion (down 6.83% YoY) and the FY2025 annual result came in at $107.8 billion, changed 0.37% from the prior year.
- Total Non-Current Liabilities eased to $106.0 billion in Q2 2026 per JNJ's latest filing, from $109.5 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $124.0 billion in Q2 2023 and troughed at $93.7 billion in Q4 2023.
- A 5-year average of $106.8 billion and a median of $107.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities gained 20.16% in 2023, then dropped 18.66% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $100.0 billion in 2022, then slipped by 2.31% to $97.7 billion in 2023, then rose by 9.93% to $107.4 billion in 2024, then advanced by 0.37% to $107.8 billion in 2025, then fell by 1.68% to $106.0 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $106.0 billion, $109.5 billion, and $107.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 105.99 Bn |
| Mar 29, 2026 | 109.50 Bn |
| Dec 28, 2025 | 107.80 Bn |
| Sep 28, 2025 | 103.61 Bn |
| Jun 29, 2025 | 113.76 Bn |
| Mar 30, 2025 | 114.33 Bn |
| Dec 29, 2024 | 107.40 Bn |
| Sep 29, 2024 | 106.91 Bn |
| Jun 30, 2024 | 108.30 Bn |
| Mar 31, 2024 | 100.83 Bn |
| Dec 31, 2023 | 97.69 Bn |
| Oct 1, 2023 | 93.66 Bn |
| Jul 2, 2023 | 114.14 Bn |
| Apr 2, 2023 | 123.96 Bn |
| Jan 1, 2023 | 109.45 Bn |
| Oct 2, 2022 | 100.00 Bn |
| Jul 3, 2022 | 100.83 Bn |
| Apr 3, 2022 | 103.16 Bn |
| Jan 2, 2022 | 107.46 Bn |
| Oct 3, 2021 | 108.34 Bn |